Reuters
17 Nov 2026, 21:48 UTC · 4h ago
Merck stops trials of blood cancer drug after risk assessment
Impact · against what's priced in
The trial cessation of a blood cancer drug creates a small negative drag on Merck's long-term growth prospects. While not a primary driver like Keytruda or the mRNA vaccine, it removes a pipeline asset that contributes to the growth acceleration the current price requires to justify its reverse-DCF CAGR.
- MRK−0.10
Challenges what's priced in
- The price assumes
The 12.2% revenue CAGR the reverse-DCF requires
Stopping clinical trials for a blood cancer drug reduces the pipeline's potential to deliver the high revenue growth acceleration that the current price mathematically demands but the market is skeptical of.
What MRK's price assumes · Sep 11

Top 1 mover · tap to explore




